Nano-X Imaging Ltd.

Company Overview

Business Model: NANO-X IMAGING LTD (Nanox) is focused on advancing preventive healthcare through affordable medical imaging technologies, leveraging advanced AI and a novel digital X-ray source. The Company aims to provide a seamless, end-to-end solution from scan to diagnosis. Its ecosystem comprises the Nanox.ARC (a multi-source digital tomosynthesis system), Nanox.AI (an AI-based suite of algorithms), Nanox.CLOUD (a cloud-based software platform), and Nanox.MARKETPLACE (a decentralized marketplace for radiology and cardiology experts offering teleradiology services). Nanox pursues three business models: the Subscription Model (MSaaS), its primary focus, offering the Nanox System at low or no upfront cost with a pay-per-scan fee; the CapEx Model, involving a one-time sale of the Nanox System; and the Licensing for OEM Model, where Nanox's X-ray source technology is licensed to other medical imaging companies for integration into their systems, generating upfront licensing fees and recurring royalties.

Market Position: Nanox aims to disrupt the medical imaging market by increasing accessibility and affordability globally, reducing wait times, and improving early detection rates. Its core differentiator is the Nanox.SOURCE, a novel digital MEMs semiconductor cathode X-ray source, which is designed for lower-cost production, near-instant on/off toggling, KvP/mA decoupling for multi-spectral imaging, longer lifetime, and a simplified hardware structure compared to legacy analog X-ray systems. The global medical imaging market was valued at $36.19 billion in 2020, projected to reach $56.53 billion by 2028, with X-ray equipment holding a 33.9% share in 2020. Nanox operates in a highly competitive industry dominated by large players like GE Healthcare, Siemens, and Philips, and faces competition from other digital X-ray source developers (e.g., carbon nano tube solutions), early-detection technologies (e.g., blood testing), and AI radiology solution providers (e.g., Aidoc Medical Ltd.).

Recent Strategic Developments:

• Regulatory Clearances:
  • April 28, 2023: FDA 510(k) clearance for Nanox.ARC (including Nanox.CLOUD) for human musculoskeletal system imaging (adjunctive to conventional radiography, adult patients).
  • December 4, 2024: FDA 510(k) clearance for Nanox.ARC for general use, including human musculoskeletal system, pulmonary, intra-abdominal, and paranasal sinus indications (adjunctive to conventional radiography, adult patients).
  • February 25, 2025: CE mark certification for the multi-source Nanox.ARC system (including Nanox.CLOUD) for the European market.
  • November 22, 2023: Israeli Ministry of Health approval for Nanox.ARC, including a free sale certificate.
  • Ghana: Local partner obtained approval from the Ghana Food and Drug Authority, initiating clinical scanning.
• Acquisitions (November 2021): Completed acquisitions of USARAD Holdings, Inc. (teleradiology services), MDWEB, LLC (Nanox.MARKETPLACE platform), and Zebra Medical Vision Ltd. (now Nanox AI, medical AI solutions).
• AI Product Launches/Clearances:
  • February 2024: FDA clearance for HealthFLD, an AI software for automated qualitative and quantitative analysis of liver attenuation from CT scans to detect fatty liver.
  • August 2024: FDA 510(k) clearance for HealthCCSng V2.0, an upgraded cardiac AI solution for detecting coronary artery calcium.
  • Ongoing development of a pulmonary AI solution, expected to be the first AI application specifically for the Nanox.ARC.
• Manufacturing & Supply Chain:
  • Commenced MEMs X-ray chip manufacturing at its Korean fabrication facility.
  • Entered into a contract manufacturing agreement with FoxSemicon Integrated Technology, Inc. (FITI) for mass production of Nanox.ARC.
  • Signed a manufacture and supply agreement with Varex Imaging Corporation (September 2023) for X-ray tubes utilizing Nanox digital X-ray emitter.
  • Entered into a development and purchase agreement with SKAN-X Radiology Devices SRL (December 2024) for X-ray tubes using Nanox semiconductor chips.
  • Collaborating with CSEM (Switzerland) for additional chip supply, with production quality chips scheduled for 2025.
• Go-to-Market Strategy:
  • U.S. market: Concentrated initial commercialization and deployment efforts on select states, targeting outpatient facilities (orthopedic clinics, skilled nursing facilities, freestanding emergency departments, urgent care facilities) with a hybrid MSaaS and CapEx model.
  • EU market: Expects initial sales primarily through the CapEx model, with distributors managing sales, regulatory approvals, and support.
• Nanox.CONNECT: Entered a supply agreement with Re-medi Co Ltd. (August 2022) to integrate 2D imaging systems with Nanox.CLOUD and Nanox.MARKETPLACE, creating a mobile 2D X-ray system, currently deployed in several beta sites.
• Corporate Structure: Incorporated Nanox Impact Inc. (January 1, 2024) in Delaware for U.S. deployment operations.

Geographic Footprint: Nanox is incorporated in Israel, where its principal executive offices and significant R&D operations are located. It has a fabrication facility in South Korea for MEMs X-ray chips. U.S. operations include subsidiaries (Nanox Imaging Inc., Nano-X MDW Inc., Nanox-X AI Inc., Nanox Impact Inc.) for teleradiology services, AI solutions, and Nanox System deployment. The Company aims for global commercialization, including North America, Asia, Europe, Africa, Latin America, and Australia. Approximately 98% of total revenue in 2024 was derived from the United States.

Cross-Border Operations: Nanox operates through wholly-owned subsidiaries in Japan (inactive), South Korea, and the United States, and has a wholly-owned AI subsidiary in Israel with a U.S. subsidiary. The Company engages in collaboration agreements and MSaaS agreements for global deployment, though some MSaaS agreements are currently on freeze (e.g., Russia and Belarus). Its supply chain involves international manufacturers and suppliers for Nanox.ARC components. Nanox is subject to multi-jurisdictional regulatory frameworks, including FDA (U.S.), CE mark (Europe), Israeli Ministry of Health, Ghana Food and Drug Authority, and various data protection laws (HIPAA, GDPR, Israeli PPL, U.S. state laws, EU Data Act, EU AI Act, Colorado AI Act).

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: -94.0%
• Operating Margin: -502.9%
• Net Margin: -474.3%

Investment in Growth:

• R&D Expenditure: $20.182 million (179.0% of revenue)
• Capital Expenditures: $2.767 million (Purchase of property and equipment)
• Strategic Investments: $1.0 million investment in Re-medi Co Ltd. (2022) for approximately 1% of shares, related to collaboration in high voltage power supply for Nanox.ARC.

Currency Impact Analysis: The U.S. dollar is Nanox's functional and reporting currency. A portion of operating expenses are incurred in New Israeli Shekels (NIS) and Korean Won (KRW). The Company is exposed to risks from NIS and KRW appreciation relative to the U.S. dollar, or if inflation in Israel or Korea exceeds the rate of devaluation of their respective currencies, which would increase the dollar cost of operations. Nanox generally lacks specific currency hedging arrangements to mitigate these risks.

Business Segment Analysis

Nanox.ARC

Financial Performance:

• Revenue: $0.281 million (+142.2% YoY)
• Operating Margin: -14800% (Operating loss of $(41.591) million on revenue of $0.281 million)
• Key Growth Drivers: Commercial deployment of the Nanox System following FDA clearances and CE mark certification. Strategic U.S. go-to-market efforts targeting outpatient facilities, building clinical evidence, and seeking reimbursement. Development of the Nanox.ARC X, a new version with a smaller footprint and enhanced features.

Product Portfolio:

• Nanox.ARC: Multi-source 3D digital tomosynthesis imaging system, integrating the proprietary Nanox.SOURCE digital X-ray source.
• Nanox.CLOUD: Cloud-based software platform for image management, radiologist matching, AI diagnostics, billing, monitoring, and reporting.
• Nanox.ARC X: A future version designed with a smaller footprint, anticipated one-day setup, "plug and play" functionality, and image enhancement options.
• Regulatory Status: FDA 510(k) clearances for musculoskeletal (April 2023) and general use including pulmonary, intra-abdominal, and paranasal sinus indications (December 2024). CE mark certification (February 2025).

Market Dynamics:

• Competitive Positioning: Aims to offer a more accessible and affordable advanced imaging solution compared to traditional CT and X-ray systems.
• Key Customer Types: Outpatient facilities, orthopedic clinics, skilled nursing facilities, freestanding emergency departments, and urgent care facilities, particularly in the U.S.
• Regional Market Trends: U.S. market shows interest in the Nanox System's clinical benefits and affordable approach. EU market is expected to favor the CapEx model initially.
• Regulatory Environment: Subject to FDA, Israeli Ministry of Health, Ghana Food and Drug Authority, and European CE mark regulations, along with state-specific U.S. approvals.

Geographic Revenue Distribution:

• United States: Primary focus for deployment and commercialization, with initial efforts concentrated in select states.
• Ghana: Clinical scanning of patients has commenced following local regulatory approval.
• Israel: Nanox.ARC is registered as a commercial medical device, and clinical trials are ongoing at Shamir hospital and Beilinson Hospital.

AI Solutions

Financial Performance:

• Revenue: $0.727 million (+122.3% YoY)
• Operating Margin: -1663.3% (Operating loss of $(12.092) million on revenue of $0.727 million)
• Key Growth Drivers: Development of machine learning platforms leveraging a database of over 500 million imaging scans. Recent FDA clearances for new AI solutions and ongoing collaborations with healthcare entities.

Product Portfolio:

• Nanox AI: Develops machine learning platforms for medical imaging solutions, with 8 FDA-cleared and 11 CE-marked AI solutions.
• HealthFLD (FDA cleared Feb 2024): Provides automated qualitative and quantitative analysis of liver attenuation from CT scans to detect fatty liver.
• HealthCCSng V2.0 (510(k) cleared Aug 2024): An upgraded cardiac solution for detecting coronary artery calcium.
• HealthOST: Assesses vertebral compression fractures and bone mineral density.
• Future Development: A pulmonary AI solution is under development, intended as the first AI application specifically for the Nanox.ARC.

Market Dynamics:

• Competitive Positioning: Competes with established AI radiology solution providers like Aidoc Medical Ltd. and legacy healthcare technology companies expanding into AI. Nanox AI focuses on identifying undiagnosed or underdiagnosed medical conditions through existing CT scans.
• Key Customer Types: Hospitals, health maintenance organizations (HMOs), integrated delivery networks (IDNs), marketplaces, pharmaceutical companies, insurers, and direct end-consumers via second opinions platforms.
• Regional Market Trends: Sales and marketing efforts are concentrated in the U.S., EU, and UK markets.
• Regulatory Environment: Subject to FDA and CE mark regulations, as well as evolving AI-specific regulations such as the EU Artificial Intelligence Act and the Colorado AI Act.

Teleradiology Services

Financial Performance:

• Revenue: $10.275 million (+8.6% YoY)
• Operating Margin: -29.8% (Operating loss of $(3.063) million on revenue of $10.275 million)
• Key Growth Drivers: Strong customer retention and increased volume of reading services, particularly during weekday shifts. Leveraging a network of accredited independent radiologists.

Product Portfolio:

• USARAD Holdings Inc.: Provides imaging interpretation services for radiology practices, hospitals, medical clinics, diagnostic imaging centers, mobile imaging service providers, urgent care facilities, and multi-specialty physician groups.
• Nanox.MARKETPLACE: A proprietary decentralized platform connecting imaging facilities with radiologists for remote interpretations.
• Second Opinions: A platform connecting patients with radiologists and other subspecialty physicians for additional medical consultation.

Market Dynamics:

• Competitive Positioning: Operates in a highly competitive, rapidly evolving, and fragmented teleradiology market, facing pressure from both large and small-scale service providers. Principal competitors include StatRad, ONRAD, and Radiology Partners.
• Key Customer Types: Daytime customers (urgent care facilities, stand-alone imaging facilities, outpatient imaging centers) and night-time/weekend customers (hospitals, community hospitals).
• Regional Market Trends: Primarily focused on the U.S. market, with services also offered in six other countries by U.S.-based radiologists.
• Regulatory Environment: Subject to state licensure laws for physicians, corporate practice of medicine laws, and anti-markup rules for Medicare, which can vary by state and impact reimbursement.

International Operations & Geographic Analysis

Revenue by Geography:

International Business Structure:

• Subsidiaries: NANO-X IMAGING LTD operates through several wholly-owned subsidiaries: Nanox Imaging Inc. (Japan, inactive), Nano-X Korea Inc. (South Korea), Nanox Imaging Inc. (U.S.), Nano-X MDW Inc. (U.S.), Nano-X AI Ltd. (Israel), Nanox-X AI Inc. (U.S.), and Nanox Impact Inc. (U.S.). Nanox Impact Inc. was incorporated on January 1, 2024, specifically for U.S. deployment operations of the Nanox System.
• Joint Ventures: The filing does not explicitly mention joint ventures, but refers to "collaboration agreements" and "strategic partnerships" for market penetration and technology development.
• Licensing Agreements: Nanox has a proposed Licensing Model for OEM, but has not yet entered into any such agreements.

Cross-Border Trade:

• Export Markets: The Nanox.ARC systems are being deployed globally, including in the U.S., Ghana, and Israel, with plans for broader expansion across Asia, Europe, Africa, Latin America, and Australia.
• Import Dependencies: The production of the Nanox.ARC involves manufacturers and suppliers in foreign nations for certain components, such as MEMs X-ray chips from Korea and Switzerland, and X-ray tubes from Korea, the U.S., and Italy.
• Transfer Pricing: The filing does not provide specific details on transfer pricing policies.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed in the provided filing.
• Dividend Payments: NANO-X IMAGING LTD has never declared or paid any cash dividends on its ordinary shares and does not plan to do so in the foreseeable future. The Company intends to reinvest all future earnings into developing and commercializing its technology and products, covering operating costs, and financing growth.
• Dividend Yield: Not applicable due to no dividend payments.
• Future Capital Return Commitments: No specific future capital return commitments were disclosed.

Balance Sheet Position:

• Cash and Equivalents: $39.304 million as of December 31, 2024, down from $56.377 million as of December 31, 2023.
• Total Debt: $3.061 million (current maturities of long-term loan) as of December 31, 2024.
• Net Cash Position: $36.243 million (Cash and Equivalents less Total Debt) as of December 31, 2024.
• Credit Rating: Not disclosed in the filing.
• Debt Maturity Profile: A $3.8 million long-term loan to Nano-X Korea Inc. from a Korean Bank, entered in September 2021, was extended for an additional 12 months in September 2024. Interest payments are monthly, with the principal due at the end of the loan term.

Cash Flow Generation:

• Operating Cash Flow: $(36.598) million for the year ended December 31, 2024, compared to $(44.777) million in 2023 and $(43.385) million in 2022.
• Free Cash Flow: Approximately $(39.365) million for the year ended December 31, 2024 (Operating Cash Flow of $(36.598) million minus Capital Expenditures of $2.767 million).
• Cash Conversion Metrics: Not explicitly detailed in the filing.

Currency Management:

• Cash holdings by major currencies: Cash and cash equivalents are primarily denominated in U.S. dollars.
• Natural hedging through operational diversification: Not explicitly mentioned.
• Financial hedging instruments and strategies: The Company generally lacks specific currency hedging arrangements to protect against fluctuations in the exchange rates of the NIS and KRW against the U.S. dollar.

Operational Excellence

Production & Service Model: NANO-X IMAGING LTD's production model for its core Nanox.SOURCE (MEMs X-ray chips) is primarily internal, utilizing its fabrication facility in Korea. To support commercialization scale-up, the Company has also engaged CSEM in Switzerland for additional chip supply, with production quality chips expected in 2025. For digital X-ray tubes, production occurs at the Korean facility, supplemented by supply agreements with Varex Imaging Corporation (U.S.) and SKAN-X Radiology Devices SRL (CEI, Italy). The Nanox.ARC system assembly involves a contract manufacturing agreement with FoxSemicon Integrated Technology, Inc. (FITI) for mass production, and Dagesh P.K. Ltd. in Israel for initial global deployment units. The service delivery model for the Nanox System relies on local operators and third-party contractors for day-to-day maintenance. The Nanox.CLOUD platform centralizes analytics and computing, aiming to reduce IT licensing costs and offer functionalities like AI diagnostics and remote support. Teleradiology services are provided by a network of U.S.-based, American Board of Radiology certified radiologists through USARAD Holdings, Inc.

Global Supply Chain Architecture: Key Suppliers & Partners:

• MEMs X-ray chips: Nano-X Korea Inc. (internal production), CSEM (Switzerland).
• X-ray tubes: Nano-X Korea Inc. (internal production), Varex Imaging Corporation (U.S.), SKAN-X Radiology Devices SRL (CEI, Italy).
• Nanox.ARC assembly: FoxSemicon Integrated Technology, Inc. (FITI), Dagesh P.K. Ltd. (Israel).
• Cloud infrastructure: Azure, Microsoft.
• 2D imaging systems: Re-medi Co Ltd. (Korea) for Nanox.CONNECT.
• Local operators/integrators: Engaged in various geographic regions for deployment and operation of medical imaging systems.

Facility Network:

• Manufacturing:
  • Yongin, Geonggi province, Korea: Owns an 11,889 square meter fabrication facility for MEMs X-ray chips, completed in 2021.
  • Israel: Utilizes Dagesh P.K. Ltd. for Nanox.ARC unit manufacturing.
• Research & Development: Principal executive offices in Petach Tikva, Israel, serve as a key R&D hub.
• Distribution: Local partners are responsible for importation, installation, and after-sales support in regions like the EU.

Operational Metrics:

• The Korean fabrication facility is expected to meet current MEMs X-ray chip manufacturing needs.
• The Nanox.ARC is designed for easy setup and operation, with multiple stationary X-ray tubes.
• The Nanox.CLOUD aims to streamline operations and reduce ongoing software and IT licensing costs.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: NANO-X IMAGING LTD is expanding its U.S.-based sales and service team to generate leads, manage customer relationships, and provide direct services for the Nanox System.
• Channel Partners:
  • Local Partnerships: In most countries outside the U.S., Nanox plans to market through local partners with strong national branding and operational presence. These partners are responsible for deployment, operation, training, and diagnostics.
  • USARAD Network: The Company leverages the USARAD Holdings, Inc. network to accelerate initial market penetration in the U.S.
  • Independent Service Providers: Engages independent service providers to address service needs in remote areas and minimize equipment downtime.
• Digital Platforms:
  • Nanox.CLOUD: Serves as a delivery mechanism for medical screening as a service.
  • Nanox.MARKETPLACE: A proprietary decentralized platform that connects imaging facilities with radiologists for remote interpretations.
  • Second Opinions Platform: Provided by USARAD Holdings, Inc., connecting patients with specialists for additional medical consultations.

Customer Portfolio: Enterprise Customers:

• Tier 1 Clients: Corewell (formerly Spectrum Health) is a notable early U.S. adopter of Nanox.AI solutions, having implemented HealthCCSng Cardiac and HealthOST Bone solutions.
• Strategic Partnerships: Nanox has collaboration agreements with marketplaces, integrated delivery networks (IDNs), hospitals, insurance assessment, and imaging companies for its AI solutions.
• Customer Concentration: No single customer accounted for more than 10% of total revenue or total accounts receivables in 2024, 2023, or 2022.
• Teleradiology Customers: Approximately 80 customers, representing about 240 facilities, including radiology practices, hospitals, medical clinics, diagnostic imaging centers, mobile imaging service providers, urgent care facilities, and multi-specialty physician groups.

Regional Market Penetration:

• United States: Initial commercialization and deployment efforts are concentrated in select states, targeting orthopedic clinics, skilled nursing facilities, freestanding emergency departments, and urgent care facilities.
• Europe: The go-to-market strategy anticipates initial sales primarily through the CapEx model, with distributors managing sales, local regulatory approvals, and support.
• Ghana: A local partner has secured regulatory approval, and clinical scanning of patients has commenced.
• Growth Markets: Nanox has entered into MSaaS agreements in various regions globally, although some, such as those in Russia and Belarus, are currently on freeze. The Nanox.CONNECT system is also deployed in several beta sites worldwide.

Competitive Intelligence

Global Market Structure & Dynamics

Industry Characteristics: The medical imaging industry is characterized by rapid evolution and intense competition. The global market size was $36.19 billion in 2020, with projections to grow to $56.53 billion by 2028, reflecting a CAGR of 5.8%. The X-ray equipment segment held a dominant 33.9% market share in 2020. Key trends driving industry evolution include an aging population, increasing demand for medical imaging, and the growing adoption of advanced AI-enabled diagnostic equipment for rapid diagnosis and predictive analysis. High regulatory, distribution, manufacturing, and long-term contractual costs represent significant barriers to entry for new players.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Traditional Medical Imaging Systems: Major global players such as GE Healthcare, Siemens, Philips, Hologic, Varian, Fuji, Toshiba, and Hitachi, which are well-established with substantial resources and market share.
• Digital X-ray Sources: Other companies attempting to develop alternative digital X-ray sources, particularly those utilizing carbon nano tube (CNT) technology. At least one company has commercialized a CNT-based X-ray system.
• Early-Detection Technologies: Competing approaches include blood testing and DNA screening.
• AI Imaging Solutions: Companies like Aidoc Medical Ltd., which primarily focus on life-threatening and urgent cases, and legacy healthcare technology companies such as Siemens Healthineers, which are developing their own AI-powered algorithms (e.g., AI-Rad Companion).
• Teleradiology Services: The market is highly competitive and fragmented, with key competitors including StatRad, ONRAD, and Radiology Partners, offering local, regional, and national coverage.

Regional Competitive Dynamics:

• United States and Western Regions: Nanox faces significant challenges from well-entrenched major market participants with strong political influence, which could potentially delay the deployment of its systems.
• Developing Countries: The Company is experiencing keen interest in its solutions in these markets, where the affordability and accessibility of its technology are particularly attractive.
• Teleradiology Market: This market is subject to ongoing competitive pricing pressure and radiologist compensation pressure, impacting all service providers.

Risk Assessment Framework

Strategic & Market Risks

Global Market Dynamics:

• Limited Operating History: As an initial launch-stage company, Nanox has a limited operating history and an unproven business plan, leading to expected significant future losses and a high probability of investment loss.
• Market Acceptance: Widespread market acceptance of the Nanox System is uncertain, influenced by sales effectiveness, perception of safety/efficiency, opposition from industry leaders, existing technologies, willingness to adopt the MSaaS model, economic conditions, and reimbursement levels.
• Business Model Execution: Successful execution of the Subscription, CapEx, and Licensing models on a global scale is challenging due to resource constraints, regulatory complexities, and the pace of product development.
• Competition: The medical imaging industry is highly competitive and subject to rapid technological change, with established players possessing greater resources and the potential for new, superior products or solutions to emerge.
• Geopolitical Risks: Ongoing conflicts in Israel (war with Hamas, Hezbollah, Iran) and other regions (Russia-Ukraine, social unrest in South Korea) pose risks of supply chain disruptions, increased costs, employee safety concerns, and negative impacts on global financial markets.
• Economic Conditions: Adverse changes in global economic conditions, including inflation, high interest rates, and limited credit availability, could harm business, reduce customer spending, and impact liquidity.

Operational & Execution Risks

Global Supply Chain Vulnerabilities:

• Supplier Dependency: Reliance on third-party manufacturers and suppliers (e.g., FITI, Dagesh, Varex, CEI, CSEM) for Nanox.ARC components and assembly introduces risks of insufficient capacity, delays, quality issues, increased costs, and potential intellectual property misappropriation.
• Regional Disruptions: Geopolitical events, natural disasters, or trade restrictions in key manufacturing or supply regions could severely disrupt production and deployment.
• Manufacturing Problems: Difficulties in developing and adapting manufacturing procedures for new products, including yield problems and the need for regulatory re-clearance for component changes, could lead to increased costs and delayed product delivery.
• Product Liability & Recalls: The inherent risks in marketing medical devices, including potential defects, software errors, or off-label use, could lead to product liability claims, costly recalls, and damage to reputation.
• Cloud Service Provider Reliance: Dependence on third-party cloud providers (e.g., Azure, Microsoft) for cloud offerings exposes Nanox to risks of service disruptions, data security breaches, and reputational harm.
• AI Clinical Risks: The use of AI in healthcare carries risks of misdiagnosis, misinformation, and ethical concerns, potentially leading to legal liability, regulatory actions, and reduced market acceptance.
• Radiologist Shortage: A shortage of qualified radiologists in certain markets or difficulty in retaining them could adversely affect revenue from teleradiology services.

Financial & Regulatory Risks

Currency & Financial Risks:

• Foreign Exchange: Exposure to currency fluctuations (NIS, KRW against USD) and inflation in foreign operating regions, with a general lack of specific hedging arrangements.
• Credit & Liquidity: Persistent net losses and negative cash flows necessitate additional financing, which may not be available on favorable terms, potentially curtailing development and commercialization efforts.
• Goodwill Impairment: Significant goodwill impairment charges (e.g., $7.4 million in 2023, $50.9 million in 2022) have negatively impacted financial results and shareholders' equity.
• Billing Complexities: Diverse and stringent billing requirements from various payors, potential need for new billing codes, and inadequate reimbursement rates could negatively affect revenue, cash flow, and profitability.
• Customer Financial Hardship: Financial difficulties experienced by customers could lead to delayed or defaulted payments.

Regulatory & Compliance Risks:

• Multi-Jurisdictional Compliance: Extensive and evolving government regulations in the U.S. (FDA, HIPAA, anti-kickback laws) and abroad (CE mark, GDPR, Israeli PPL, EU AI Act, EU Data Act) require continuous compliance efforts, with potential for significant penalties, enforcement actions, or market restrictions for non-compliance.
• Trade Regulations: Tariffs, export controls, and other trade restrictions could increase costs, disrupt supply chains, and limit market access.
• Tax Regulations: Changes in international tax laws, including transfer pricing rules and BEPS compliance, could impact tax liabilities.

Geopolitical & External Risks

Country-Specific Risks:

• Israel: The ongoing war and regional conflicts pose risks to operations, supply chains, employee safety, and Israel's economic standing, potentially leading to increased costs and business disruptions.
• South Korea: Political instability or civil unrest, such as the recent martial law declaration and impeachment vote, could adversely affect Nanox's supply chain.
• Trade Tensions: Escalating trade tensions between major economies (e.g., U.S. and China) could disrupt global supply chains, increase prices, and negatively impact economic conditions.
• Catastrophic Events: Natural disasters, epidemics, or other catastrophic events in operating markets could materially affect business, financial condition, and results of operations.

Innovation & Technology Leadership

Research & Development Focus: NANO-X IMAGING LTD's R&D efforts are centered on advancing its core medical imaging technologies and AI solutions. Global R&D Network:

• Israel: Serves as the Company's primary R&D hub, located at its principal executive offices in Petach Tikva.
• South Korea: Operates a fabrication facility for the manufacturing of MEMs X-ray chips, a critical component of its digital X-ray source.
• Focus Areas:
  • Nanox System: Continuous development and improvement of the Nanox.ARC multi-source 3D tomosynthesis imaging system and the Nanox.CLOUD cloud-based software platform.
  • Nanox.ARC X: Development of a new version of the Nanox System with a smaller footprint, enhanced image capabilities, and "plug and play" functionality, currently submitted for FDA clearance.
  • AI Solutions: Development of machine learning platforms and new algorithms, including a pulmonary solution designed specifically for the Nanox.ARC to identify chest diseases and lung cancer.
  • Nanox.CONNECT: Integration of 2D imaging systems with Nanox.CLOUD and Nanox.MARKETPLACE for mobile X-ray and remote reading capabilities.
• Innovation Pipeline: Clinical trials are ongoing at Shamir hospital and Beilinson Hospital in Israel to collect clinical sample images and assess the Nanox System's diagnostic capabilities for chest and lung diseases. Beta sites for Nanox.CONNECT are also deployed globally.

Intellectual Property Portfolio:

• Patent Strategy: Nanox holds a substantial patent portfolio, including 32 issued patents and 3 pending applications in the United States, 4 issued patents and 2 pending applications in Israel, 4 issued patents and 6 pending applications in the European Patent Office, 1 granted Germany Utility Model, 3 issued patents in China, 3 issued patents in Korea, and 5 issued patents and 2 pending applications in Hong Kong. These patents generally expire between 2032 and 2041 and cover various features of the Nanox.ARC, AI, and teleradiology technologies. The Company actively pursues new patent filings and defends against infringement.
• Licensing Programs: While a Licensing Model for OEM is proposed, Nanox has not yet entered into any licensing agreements.
• IP Litigation: The Company has been involved in IP-related disputes, highlighting the costs and management distraction associated with defending proprietary rights.
• Trademarks: Nanox maintains a portfolio of registered trademarks in the U.S., Brazil, Israel, China, India, Japan, the European Union, and Great Britain, and has entered into co-existence agreements for its "ARC" trademark with other entities.

Technology Partnerships:

• Re-medi Co Ltd. (Korea): A strategic collaboration involving a $1.0 million investment for approximately 1% of shares, focusing on the development of high voltage power supply for Nanox.ARC and the integration of 2D imaging systems for Nanox.CONNECT.
• CSEM (Switzerland): Partnered for additional MEMs X-ray chip supply to support commercialization scale-up.
• Varex Imaging Corporation (U.S.): A manufacturing and supply agreement for X-ray tubes utilizing Nanox's digital X-ray emitter.
• SKAN-X Radiology Devices SRL (CEI, Italy): A development and purchase agreement for the manufacture of X-ray tubes using Nanox's semiconductor chips.
• Medical AI-analytics companies: Potential collaborators for leveraging accumulated medical images through machine learning algorithms to enhance early disease detection.

Leadership & Governance

Executive Leadership Team

International Management Structure: The Company's management team includes executives with international experience and regional expertise, such as the Chief Financial Officer who is licensed in the U.S. and Israel, and the Chief Medical Officer who co-founded Remote Radiology International. Regional leadership and reporting relationships are supported by the existing international Nanox organization for operational needs.

Board Composition: The Board of Directors consists of six directors: Erez Meltzer (Acting Chairman), Noga Kainan, Dan Suesskind, Erez Alroy, Michael Jackman, and Nehama Ronen. Directors serve staggered three-year terms. Four directors qualify as independent under Nasdaq rules. The Company has opted out of certain Israeli Companies Law requirements for external directors and related committee compositions, instead complying with U.S. laws and Nasdaq rules.

• Audit Committee: Noga Kainan (Chairperson), Dan Suesskind, Nehama Ronen, and Erez Alroy. Noga Kainan and Dan Suesskind are designated as audit committee financial experts.
• Compensation Committee: Dan Suesskind (Chairperson), Noga Kainan, and Erez Alroy.
• Nominating Committee: Erez Meltzer and Nehama Ronen.

Regulatory Environment & Compliance

Multi-Jurisdictional Regulatory Framework: NANO-X IMAGING LTD operates within a complex and evolving multi-jurisdictional regulatory landscape, impacting its medical devices, AI solutions, and teleradiology services. Primary Regulatory Environments:

• United States:
  • Medical Devices: Regulated by the FDA under the Federal Food, Drug, and Cosmetic Act (FDCA) for design, manufacturing, testing, labeling, marketing, and post-market surveillance. The Nanox.ARC has received 510(k) clearances for specific uses.
  • Radiation-Emitting Devices: Subject to FDA's Electronic Product Radiation Control provisions and individual state regulations for X-ray performance and safety.
  • Healthcare Fraud & Abuse: Activities are subject to federal and state anti-kickback statutes, False Claims Act, HIPAA, HITETECH, Physician Payment Sunshine Act, and Stark Law.
  • Data Privacy & Security: Compliance with HIPAA, HITECH, and various state-specific data privacy laws (e.g., CCPA, CPRA, VCDPA, CPA, CDPA, UCPA, TDPSA, OCDPA, FDBR, MTCDPA). The Food and Drug Omnibus Reform Act (FDORA) also imposes cybersecurity requirements for "cyber devices."
  • AI Regulation: Subject to emerging state-level AI regulations, such as the Colorado AI Act (effective February 1, 2026).
• Europe (EEA):
  • Medical Devices: Products must comply with the EU Medical Devices Regulation (EU) 2017/745, requiring CE mark certification (obtained for Nanox.ARC system, including Nanox.CLOUD, on February 25, 2025).
  • Data Protection: Subject to the EU General Data Protection Regulation (GDPR), including stringent requirements for processing personal data and restrictions on cross-border data transfers. The EU-US Data Privacy Framework is utilized, though it faces legal challenges.
  • AI Regulation: Subject to the EU Artificial Intelligence Act (effective February 2025), which imposes specific obligations on AI manufacturers and developers, and the EU Data Act (most obligations effective September 2025) for data sharing and reuse.
• United Kingdom: Subject to the UK General Data Protection Regulation (UK GDPR) and evolving UK AI regulation proposals.
• Israel:
  • Medical Devices: Nanox.ARC received approval from the Medical Device Division of the Ministry of Health in November 2023.
  • Data Protection: Subject to the Israeli Privacy Protection Law (PPL) and its regulations, with Amendment 13 (effective August 14, 2025) expanding enforcement authority and monetary sanctions.
  • R&D Grants: Subject to the Innovation Law, requiring royalty payments to the Israeli Innovation Authority (IIA) on sales of products developed with grants.
• Ghana: Local partner obtained approval from the Ghana Food and Drug Authority (GFDA).

Cross-Border Compliance:

• Export Controls: The FDA regulates exports of medical devices from the United States.
• Sanctions Compliance: MSaaS agreements in certain regions, such as Russia and Belarus, are currently on freeze due to military conflicts and associated sanctions.
• Anti-Corruption: The Company is subject to various anti-bribery and anti-money laundering laws, including the U.S. Foreign Corrupt Practices Act (FCPA), the UK Bribery Act 2010, and Israeli anti-corruption laws, with risks increasing with international business expansion.
• International Tax Strategy: The Company's Israeli operations are subject to Israeli corporate tax laws, including potential tax benefits under the Investment Law (though not currently utilized) and capital gains/dividend taxation rules.

Environmental & Social Impact

Global Sustainability Strategy: NANO-X IMAGING LTD acknowledges the increasing focus on Environmental, Social, and Governance (ESG) matters from investors, customers, and other stakeholders. The Company's commitment to preventive healthcare through accessible medical imaging aligns with broader social impact goals.

Environmental Commitments:

• Climate Strategy: The Company is subject to evolving regulatory requirements related to environmental impact and sustainability, including potential new rules and regulations regarding climate-related disclosures (e.g., SEC Release No. 33-11275, currently stayed). Compliance with these demands may lead to additional manufacturing, operating, or product development costs.
• Regional Sustainability Initiatives: The Company's supply chain is subject to global supplier ESG requirements and sustainability standards.

Social Impact by Region:

• Community Investment: Not explicitly detailed in the filing.
• Labor Standards: The Company is subject to federal and state employment and labor laws and regulations across its operating jurisdictions, covering working conditions, wage-hour pay, employee benefits, and anti-discrimination. Compliance with these laws is critical, and non-compliance could lead to investigations and penalties.
• Human Capital Management: Objectives include identifying, recruiting, retaining, incentivizing, and integrating employees, advisors, and consultants. Equity and cash incentive plans are designed to attract and retain highly qualified personnel.
• Employee Health and Safety: Not explicitly detailed beyond general compliance with labor laws.

Currency Management & Financial Strategy

Multi-Currency Operations: NANO-X IMAGING LTD's functional and reporting currency is the U.S. dollar. However, a significant portion of its operating expenses, including personnel and facilities-related costs, are incurred in New Israeli Shekels (NIS) and Korean Won (KRW). This exposes the Company to foreign currency exchange rate fluctuations.

Currency Exposure:

Hedging Strategies:

• Transaction Hedging: The Company generally lacks specific currency hedging arrangements to protect against short-term foreign exchange risk.
• Translation Hedging: Not explicitly detailed, but the general lack of hedging arrangements suggests limited strategies for balance sheet currency exposure.
• Economic Hedging: Not explicitly detailed. The Company's exposure to foreign currency exchange risk means that an appreciation of the NIS or KRW relative to the U.S. dollar, or if inflation in Israel or Korea outpaces the devaluation of their respective currencies, would increase the dollar cost of its operations and adversely affect its dollar-denominated results.